fda bans bpc 157 This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the will make Did the FDA Just Approve

Known side effects Both BPC-157 and TB-500 show relatively favorable side effect profiles in reported use

The absence of systematic monitoring is one of the most common shortcomings in patient-initiated peptide use, and it is precisely what differentiates responsible clinical supervision from unsupervised self-experimentation

Benzyl alcohol is contraindicated in neonates, and healthcare providers strongly advise against its use in this population

PCAC review (July 2026) The FDA stated it intends to consult the Pharmacy Compounding Advisory Committee on July 23, 2026 regarding inclusion of BPC-157 acetate and BPC-157 (free base) on the 503A bulks list